FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922346901> ?p ?o ?g. }

• W2922346901 endingPage "1199" @default.
• W2922346901 startingPage "1190" @default.
• W2922346901 abstract "The SUSTAIN 3 and 7 clinical trials compared the efficacy and safety of once-weekly semaglutide relative to exenatide extended-release (ER) and dulaglutide, respectively, in the treatment of patients with type 2 diabetes (T2D). The trials included a series of clinically relevant single and composite endpoints focused on improving glycemic control and reducing body weight, while avoiding hypoglycemia. The present study combined SUSTAIN 3 and 7 outcomes with short-term treatment costs to evaluate the relative cost of control of once-weekly semaglutide versus exenatide ER and dulaglutide.Proportions of patients reaching three endpoints were taken from SUSTAIN 3 and 7 for comparisons with exenatide ER and dulaglutide, respectively. The endpoints investigated were HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia or weight gain, and a ≥ 1.0% HbA1c reduction with ≥ 5.0% weight loss. Annual per patient treatment costs were based on US wholesale acquisition costs from July 2018. Relative cost of control was calculated by plotting the ratio of the treatment costs and the ratio of the proportions of patients reaching each endpoint on the cost-efficacy plane.Once-weekly semaglutide 0.5 mg and 1.0 mg were most effective at bringing patients to each of the three endpoints across both SUSTAIN trials. The efficacy-to-cost ratios for once-weekly semaglutide 0.5 mg and 1.0 mg were also superior to all comparators when assessing both the single endpoint of HbA1c < 7.0% and the two composite endpoints including weight loss and hypoglycemia.The present study showed that once-weekly semaglutide 0.5 mg and 1.0 mg offer superior cost of control versus exenatide ER and dulaglutide in terms of achieving single and composite endpoints, based on an analysis of retrieved dropout data. Once-weekly semaglutide 0.5 mg and 1.0 mg would therefore represent good value for money in the USA, particularly in the attainment of multi-model T2D treatment goals.Novo Nordisk A/S." @default.
• W2922346901 created "2019-03-22" @default.
• W2922346901 creator A5034860372 @default.
• W2922346901 creator A5038827564 @default.
• W2922346901 creator A5051180257 @default.
• W2922346901 creator A5072605000 @default.
• W2922346901 creator A5086488422 @default.
• W2922346901 date "2019-03-14" @default.
• W2922346901 modified "2023-10-07" @default.
• W2922346901 title "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA" @default.
• W2922346901 cites W1526927233 @default.
• W2922346901 cites W2019499897 @default.
• W2922346901 cites W2089770071 @default.
• W2922346901 cites W2111824270 @default.
• W2922346901 cites W2146392529 @default.
• W2922346901 cites W2170271198 @default.
• W2922346901 cites W2171294019 @default.
• W2922346901 cites W2186808074 @default.
• W2922346901 cites W2188846692 @default.
• W2922346901 cites W2271771390 @default.
• W2922346901 cites W2302447233 @default.
• W2922346901 cites W2337454357 @default.
• W2922346901 cites W2774157762 @default.
• W2922346901 cites W2787255324 @default.
• W2922346901 cites W2794276124 @default.
• W2922346901 cites W2801768830 @default.
• W2922346901 cites W2808825425 @default.
• W2922346901 cites W2895485676 @default.
• W2922346901 cites W2898542079 @default.
• W2922346901 cites W3092065440 @default.
• W2922346901 cites W4213210402 @default.
• W2922346901 cites W4214911496 @default.
• W2922346901 cites W4232925197 @default.
• W2922346901 doi "https://doi.org/10.1007/s12325-019-00915-8" @default.
• W2922346901 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6824375" @default.
• W2922346901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30980280" @default.
• W2922346901 hasPublicationYear "2019" @default.
• W2922346901 type Work @default.
• W2922346901 sameAs 2922346901 @default.
• W2922346901 citedByCount "6" @default.
• W2922346901 countsByYear W29223469012019 @default.
• W2922346901 countsByYear W29223469012020 @default.
• W2922346901 countsByYear W29223469012021 @default.
• W2922346901 crossrefType "journal-article" @default.
• W2922346901 hasAuthorship W2922346901A5034860372 @default.
• W2922346901 hasAuthorship W2922346901A5038827564 @default.
• W2922346901 hasAuthorship W2922346901A5051180257 @default.
• W2922346901 hasAuthorship W2922346901A5072605000 @default.
• W2922346901 hasAuthorship W2922346901A5086488422 @default.
• W2922346901 hasBestOaLocation W29223469011 @default.
• W2922346901 hasConcept C126322002 @default.
• W2922346901 hasConcept C134018914 @default.
• W2922346901 hasConcept C168563851 @default.
• W2922346901 hasConcept C203092338 @default.
• W2922346901 hasConcept C2777180221 @default.
• W2922346901 hasConcept C2779306644 @default.
• W2922346901 hasConcept C2779829264 @default.
• W2922346901 hasConcept C2780473172 @default.
• W2922346901 hasConcept C2780533449 @default.
• W2922346901 hasConcept C2780668416 @default.
• W2922346901 hasConcept C2781308992 @default.
• W2922346901 hasConcept C2909862629 @default.
• W2922346901 hasConcept C511355011 @default.
• W2922346901 hasConcept C535046627 @default.
• W2922346901 hasConcept C544821477 @default.
• W2922346901 hasConcept C555293320 @default.
• W2922346901 hasConcept C71924100 @default.
• W2922346901 hasConceptScore W2922346901C126322002 @default.
• W2922346901 hasConceptScore W2922346901C134018914 @default.
• W2922346901 hasConceptScore W2922346901C168563851 @default.
• W2922346901 hasConceptScore W2922346901C203092338 @default.
• W2922346901 hasConceptScore W2922346901C2777180221 @default.
• W2922346901 hasConceptScore W2922346901C2779306644 @default.
• W2922346901 hasConceptScore W2922346901C2779829264 @default.
• W2922346901 hasConceptScore W2922346901C2780473172 @default.
• W2922346901 hasConceptScore W2922346901C2780533449 @default.
• W2922346901 hasConceptScore W2922346901C2780668416 @default.
• W2922346901 hasConceptScore W2922346901C2781308992 @default.
• W2922346901 hasConceptScore W2922346901C2909862629 @default.
• W2922346901 hasConceptScore W2922346901C511355011 @default.
• W2922346901 hasConceptScore W2922346901C535046627 @default.
• W2922346901 hasConceptScore W2922346901C544821477 @default.
• W2922346901 hasConceptScore W2922346901C555293320 @default.
• W2922346901 hasConceptScore W2922346901C71924100 @default.
• W2922346901 hasIssue "5" @default.
• W2922346901 hasLocation W29223469011 @default.
• W2922346901 hasLocation W29223469012 @default.
• W2922346901 hasLocation W29223469013 @default.
• W2922346901 hasLocation W29223469014 @default.
• W2922346901 hasOpenAccess W2922346901 @default.
• W2922346901 hasPrimaryLocation W29223469011 @default.
• W2922346901 hasRelatedWork W1989713397 @default.
• W2922346901 hasRelatedWork W2738743019 @default.
• W2922346901 hasRelatedWork W2799735051 @default.
• W2922346901 hasRelatedWork W2948380809 @default.
• W2922346901 hasRelatedWork W2948622224 @default.
• W2922346901 hasRelatedWork W2979558564 @default.
• W2922346901 hasRelatedWork W3166343083 @default.

• next